cambridge.org/neu

## Perspective

**Cite this article:** Arjmand S, Ilaghi M, Shafie'ei M, Gobira PH, Grassi-Oliveira R, and Wegener G. (2025) Exploring the potential link between  $\Delta$ FosB and *N*-acetylcysteine in craving/relapse dynamics: can *N*-acetylcysteine stand out as a possible treatment candidate? *Acta Neuropsychiatrica*. **37**(e31), 1–14. doi: 10.1017/neu.2024.38

Received: 15 December 2023 Revised: 3 June 2024 Accepted: 7 June 2024

### Keywords:

 $\Delta$ FosB; N-acetylcysteine; relapse; substance use disorders; reinstatement

### **Corresponding author:**

Gregers Wegener; Email: wegener@clin.au.dk

© The Author(s), 2024. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/ by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.



Exploring the potential link between  $\Delta$ FosB and *N*-acetylcysteine in craving/relapse dynamics: can *N*-acetylcysteine stand out as a possible treatment candidate?

Shokouh Arjmand<sup>1</sup><sup>®</sup>, Mehran Ilaghi<sup>2</sup><sup>®</sup>, Mohammad Shafie'ei<sup>3</sup>, Pedro H. Gobira<sup>1</sup>, Rodrigo Grassi-Oliveira<sup>1</sup> and Gregers Wegener<sup>1,4</sup><sup>®</sup>

<sup>1</sup>Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; <sup>2</sup>Institute of Neuropharmacology, Kerman Neuroscience Research Center, Kerman University of Medical Sciences, Kerman, Iran; <sup>3</sup>Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran and <sup>4</sup>Department of Affective Disorders, Aarhus University Hospital–Psychiatry, Aarhus, Denmark

### Abstract

From a neuroscientific point of view, one of the unique archetypes of substance use disorders is its road to relapse, in which the reward system plays a crucial role. Studies on the neurobiology of substance use disorders have highlighted the central role of a protein belonging to the Fos family of transcription factors,  $\Delta$ FosB. Relying on the roles  $\Delta$ FosB plays in the pathophysiology of substance use disorders, we endeavour to present some evidence demonstrating that *N*-acetylcysteine, a low-cost and well-tolerated over-the-counter medicine, may influence the downstream pathway of  $\Delta$ FosB, thereby serving as a treatment strategy to mitigate the risk of relapse in cases of substance use.

### **Summation**

- ΔFosB is a critical component in relapse and reinstatement to substance use disorders that is highly expressed after repeated chronic administration of drugs of abuse, targetting glutamate release, spine density, transcriptional factors, and epigenetic mechanisms.
- Modulation of  $\Delta$ FosB's targets and upstream pathways might be a strategy to prevent relapse.
- Evidence suggests that N-acetylcysteine can potentially help reduce drug use relapse and craving. Here, we explored potential mechanisms through which N-acetylcysteine impacts dendritic arborisation, synaptic plasticity, transcriptional downstream targets, and epigenetics. These mechanisms may provide a possible link to  $\Delta$ FosB-related signalling in drug use relapse and craving.

### Perspective

- N-acetylcysteine influences glutamatergic and dopaminergic neurotransmission and modulates downstream signalling transcription factors and pathways altered by  $\Delta$ FosB, making it a promising treatment option for preventing relapse in substance use.
- N-acetylcysteine's safety profile, tolerability, and accessibility give this compound a significant advantage for use in this context, particularly since patients with substance use disorders are prone to the risk of overdose.
- Further extensive and robust preclinical and clinical research is needed to confirm the efficacy of N-acetylcysteine and to uncover the underpinning mechanisms behind its effects.

## A glance at the reward system in substance use disorders

Although different drugs of abuse act on distinct neurotransmitter systems of the brain and engender various psychoactive effects, all of them converge on the brain's reward system (Nestler, 2005). Preclinical studies on substances abused by humans have provided us with better insights into addiction's cellular and molecular pathways (Lynch *et al.*, 2010). Studies on experimental animals have shown that both acute and chronic drug self-administration

dramatically enhance the firing of the dopaminergic neurons of the ventral tegmental area (VTA) of the midbrain, an area with reciprocal projections to and from the mesocortical and mesolimbic pathways, including the nucleus accumbens (NAc) of the limbic forebrain, amygdala, cingulate gyrus, basal ganglia, and prefrontal cortex (PFC) (Nestler, 2005; Willuhn *et al.*, 2010; Volkow and Morales, 2015).

All drugs of abuse are potentially rewarding. The NAc, amygdala (particularly the basolateral amygdala), ventromedial prefrontal cortex (including the orbitofrontal cortex), and posterior cingulate cortex are among the cortical and subcortical areas involved in the valuation and reward process. These areas evaluate the value, history, and cost of a reward and whether a rewarding activity needs to be repeated (Nestler, 2005; Wassum and Izquierdo, 2015; Loganathan and Ho, 2021). Increased VTA's dopaminergic signalling will cause a sudden rise in the cyclic AMP (cAMP) and Ca<sup>2+</sup> concentration in the NAc, following the activation of D<sub>1</sub> receptors and, therefore, activate adenylyl cyclase (Muschamp and Carlezon, 2013). All these events subsequently lead to the activation of the cAMP response element-binding protein (CREB) through the phosphorylation of Ser<sup>133</sup> (Muschamp and Carlezon, 2013).

CREB is a transcription factor that can either enhance or repress the expression of several genes. Phosphorylation of CREB at Ser<sup>133</sup> results in the increased expression of dynorphin, which occupies kappa opioid receptors located on the VTA neurons and hampers the dopamine signalling of the mesocorticolimbic pathway of the reward circuitry. Thus, tolerance and dependence instigate, causing patients with substance use disorders to use more of a substance (Nestler, 2005; Muschamp and Carlezon, 2013).

On the other side, with chronic use of addictive substances, several structural modifications and many cellular adaptations will occur (Robinson and Kolb, 1997; Spiga et al., 2014; Zhang et al., 2017). Dopamine signalling of the VTA-NAc pathway also produces another protein named  $\Delta$ FosB, which leads to the activation of several other genes switched on by phosphorylated CREB and suppression of dynorphin synthesis (McClung and Nestler, 2003; Nestler, 2005, 2012). Activation of these genes will result in the production of proteins in charge of responses sensitised to drugs of abuse, including nuclear factor kappa B (NF- $\kappa$ B) and cyclin-dependent kinase 5 (Cdk5), both of which can also result in structural alterations of the NAc, making it hypersensitive to addictive substances and drug-related cues (McClung and Nestler, 2003; Nestler, 2005, 2012). In this stage, the hippocampus also plays a part in the formation of context-specific memories of such experiences to remember the who, the where, the when, and the how of drug self-administration (contextual conditioning) and altogether build a road to relapse (Goodman and Packard, 2016; Silva et al., 2016).  $\Delta$ FosB also contributes to the growth of NAc's dendritic spines where it has been generated, and these sprouted branches of NAc's dendritic spines make it more sensitized to the VTA signalling and will last even months after degradation of  $\Delta$ FosB (Maze *et al.*, 2010; Nestler, 2005, 2012). Upon withdrawal or abstinence, this established hypersensitivity and strong memory will result in craving, compulsive drug-seeking behaviours, and relapse (Nestler, 2005; Milton and Everitt, 2012).

After days of abstinence, the level of CREB remarkably wanes, while  $\Delta$ FosB's level, due to its considerable long half-life, will remain steady and reach a plateau for weeks and months even when substance use has ceased. Hence, the diminished concentration of CREB will open a door for the domination of  $\Delta$ FosB's deteriorating effects (Figure 1), leading to craving and drugseeking behaviours (Nestler, 2005, 2012). We are still in search of efficient, improved treatment strategies to markedly hamper craving and reduce relapse and reinstatement associated with chronic use of drugs of abuse. Having better insights into the driving forces behind reinstatement can potentially shed light on the better management of substance use disorders in the future. Based on the accumulating evidence on  $\Delta$ FosB's role in substance use relapse, the following section digs deep into how  $\Delta$ FosB plays a crucial role in substance use relapse, laying the foundation for understanding how targeting this molecule and its associated signalling pathways could be a way to lessen craving.

## $\varDelta {\rm FosB}$ as a molecular target in substance use disorders treatment

 $\Delta$ FosB is a 33–37 kDa protein that belongs to the Fos family of transcription factors, which can form either a heterodimer with the Jun family of proteins, particularly JunD or form stable molecular assemblies on its own (Wang *et al.*, 2012; Yin *et al.*, 2020). Such heterodimerization shapes functional activator protein 1 (AP-1) complexes that can be attached to the AP-1 sites, regulating the transcription of various genes (Nestler, 2001, 2008).

Distinct from other FosB proteins,  $\Delta$ FosB is bereft of 101 Cterminal amino acids, making it lack two degron domains and, consequently, less prone to degradation (Figure 2) (Carle et al., 2007; Wang et al., 2012; Zhang et al., 2014). Moreover, phosphorylation of a well-preserved serine residue (Ser27) of  $\Delta$ FosB *via* either previously surmised casein kinase 2 (Ulery *et al.*, 2006) or more recently explored  $Ca^{2+}/calmodulin-dependent$ protein kinase (CaMKII) (Robison et al., 2013) prevents degradation of this protein, leading to its long half-life (around 8 days in vivo) (Figure 2). Such longevity confers disparate responses in gene expression after acute and chronic administration of drugs of abuse and makes  $\Delta$ FosB stable enough to remain active for several weeks even after cessation of drug exposure or drug withdrawal (Figure 1) (Nestler, 2008). Data have shown that such durability is not correlated with  $\Delta$ FosB's mRNA long life but rather the protein per se (Kelz and Nestler, 2000).

Unlike most Fos family members whose expression is triggered by acute exposure to drugs of abuse and only lasts for hours,  $\Delta$ FosB is highly expressed in the striatal regions in a medium spiny neuron (MSN)-subtype-selective pattern after repeated chronic administration (Olsen, 2011; Lobo *et al.*, 2013a; Zhang *et al.*, 2014). Accordingly, numerous drugs of abuse induce  $\Delta$ FosB only in MSNs-expressing dopamine D1 receptors, whereas others, such as opioids, induce  $\Delta$ FosB equally in D1- and D2-MSNs (Lobo *et al.*, 2013b). Similarly, a recent study has shown that chronic cocaine use induced broad changes in  $\Delta$ FosB binding in both D1- and D2-MSNs in NAc (Yeh *et al.*, 2023). On the other hand, prolonged administration of some antipsychotic medications induces  $\Delta$ FosB exclusively in D2-MSNs (Lobo *et al.*, 2013b).

Additionally, recent data indicate that, besides the MSN subtype,  $\Delta$ FosB mediates distinct transcriptional effects in males and females (Lardner *et al.*, 2021). Induction of  $\Delta$ FosB in each subtype of MSNs (D1- vs. D2-MSNs) led to sex- and MSN-specific control of transcripts. In female NAc, induction of  $\Delta$ FosB in D1-MSNs resulted in opposite regulation compared to D2-MSNs (Lardner *et al.*, 2021). Moreover, little overlap was seen among regulatory downstream genes when males and females were compared after induction of  $\Delta$ FosB in each specific MSN subtype (Lardner *et al.*, 2021). Although the sex-specific transcriptional effects of  $\Delta$ FosB are less studied, these findings are of utmost



**Figure 2.** Structure of  $\Delta$ FosB and other Fos proteins. Compared to other Fos proteins,  $\Delta$ FosB lacks the 101 C-terminal amino acids and the degron domains responsible for ubiquitin- and proteasome-dependent and independent degradation, thus enhancing its stability. Additionally, Ser27 phosphorylation by Casein Kinase 2 and Ca<sup>2+</sup>/calmodulin-dependent protein kinase (CaMKII) prevents decomposition of this protein, leading to its long-term half-life.

importance since there are notable sex differences throughout the progression of various substance use disorders and their comorbid conditions (Daiwile *et al.*, 2022b; Chapp *et al.*, 2022a, 2024). Although women tend to be engaged with drugs less frequently than men, they often progress more rapidly to meet the criteria for substance use disorders and may experience more severe psychiatric disturbances compared to men (Cadet, 2021). Additionally, women are generally more prone to relapse (for a

comprehensive review, see (Becker and Koob, 2016)). Therefore, the preliminary findings of Lardner et al., on sex-specific transcriptional effects of  $\Delta$ FosB have significant implications for understanding the pathophysiology underlying relapse and the use of potential drugs in preventing relapse (Lardner *et al.*, 2021).

Although it has been shown that  $\Delta$ FosB's distribution in the different parts of the striatum is diverse when various drugs are abused, nearly all of them induce the accumulation of  $\Delta$ FosB in the

NAc (Perrotti *et al.*, 2008). Besides, findings have suggested that the accumulation of  $\Delta$ FosB induced by addictive substances targets the dynorphin-containing class of MSNs (Kelz and Nestler, 2000).

Gajewski et al., have also demonstrated that the expression profile of  $\Delta$ FosB differs in various brain regions associated with substance use disorders. They reported a reduced level of  $\Delta$ FosB in the hippocampus but not in the prefrontal cortex, which is supported by the observation that even some investigated upstream target genes, such as GluA2 and CaMKII, are also downregulated solely in the hippocampus (Gajewski *et al.*, 2016).

These observations suggest that  $\Delta$ FosB could be one of the main contributing molecules of reinstatement. In this regard, studies on animal models of relapse have demonstrated that overexpression of  $\Delta$ FosB not only sensitises the rewarding effect of drugs of abuse but also produces increased drug-seeking behaviour that leads to relapse (Kelz *et al.*, 1999; Colby *et al.*, 2003; Zachariou *et al.*, 2006). Of note, McClung et al., have implied that short or long-term expression of  $\Delta$ FosB acts oppositely and thus leaves distinct outcomes (McClung and Nestler, 2003). They showed that  $\Delta$ FosB's short-term expression in the NAc upregulates many of the same genes as CREB, presumably *via* direct effect. However, the scenario turned back in case of either overexpression or prolonged elevation of  $\Delta$ FosB, which facilitates the induction of transcriptional downregulation of genes that CREB had upregulated and vice versa (McClung and Nestler, 2003).

Besides preclinical studies, post-mortem analyses of the brain tissues of chronic opioid abusers have revealed enhanced expression of  $\Delta$ FosB in the NAc that was followed by a rise in the level of its downstream targets such as Cdk5, NF- $\kappa$ B, CREB, brain-derived neurotrophic factor, and JunD in both the hippocampus and NAc (Seltenhammer *et al.*, 2016). They confirmed that  $\Delta$ FosB and its downstream transcriptional targets are critical to inducing sustainable brain changes and establishing a strong memory associated with drugs of abuse on the road to dependency and relapse (Seltenhammer *et al.*, 2016).

The dimerisation of  $\Delta$ FosB with JunD possibly circumvents CREB on being attached to the cAMP response element (CRE) site and, as a result, acts contrariwise to that of CREB. It can also be postulated that higher levels of  $\Delta$ FosB may act as an AP-1 activator (McClung and Nestler, 2003). Finally, CaMKII, a protein upregulated as  $\Delta$ FosB is continuously overexpressed, has been introduced as another potential candidate for these observations (McClung and Nestler, 2003; Robison *et al.*, 2013). CaMKII hinders the dimerisation of CREB with CREB binding protein via phosphorylating CREB (McClung and Nestler, 2003).

In a study conducted by Vialou et al., following chronic cocaine administration, expression of both CREB and serum response factor (SRF) were shown to be essential for the accumulation and regulation of NAc's  $\Delta$ FosB (Vialou *et al.*, 2012; Eagle *et al.*, 2019). They concluded that upstream modulation of  $\Delta$ FosB requires the adequate expression of both transcription factors and deletion of either could not prevent the accumulation of  $\Delta$ FosB in the NAc (Vialou *et al.*, 2012; Eagle *et al.*, 2019).

There are also studies pointing to RNA-binding proteins involved in regulating  $\Delta$ FosB. Recent evidence suggests synergistic effects of D1 dopaminergic and activin receptor-like kinase 4 (ALK4) signalling, mediated by activation of poly-binding protein 1 (PCBP1) and Smad3 in MSNs of NAc, induce  $\Delta$ FosB production and its reward-related behaviour (Krapacher *et al.*, 2022). Enhanced expression of an RNA-binding protein called polypyrimidine tract-binding protein 1 (PTBP1) was suggested to cause reduced transcription of  $\Delta$ FosB (Alibhai *et al.*, 2007; Bryant and Yazdani, 2016). Another study pointed out that elevation in the level of  $\Delta$ FosB can be modulated by intraperitoneal administration of molecular hydrogen in methamphetamine-dependent mice (Wen *et al.*, 2020). Wen et al. also showed that molecular hydrogen (delivered by the administration of hydrogen-rich saline) reduces behavioural sensitisation by acting as an antioxidant, inhibiting the production of superoxide anion, and diminishing the amount of phosphorylated ERK and  $\Delta$ FosB in the NAc (Wen *et al.*, 2020).

Interestingly, this observed overexpression is not only limited to the drugs of abuse but also other compounds, such as sweeteners that activate the brain's reward system (Salaya-Velazquez et al., 2020) and even stressful conditions (Perrotti et al., 2004; Scalize Hirata et al., 2019). Keeping all these in mind, it is worth mentioning that stress and stressful adverse events in life can not only lead to addiction but also predispose abstained patients with substance use disorders to reinstate and relapse (Goeders, 2003; Sinha, 2008, 2012). Though different mechanisms contribute to such phenomena, assessing the role stress plays in manipulating  $\Delta$ FosB toward an increased susceptibility to relapse is not out of reason. A study has shown that repeated social defeat stress significantly enhances the expression of  $\Delta$ FosB in the frontal cortex, shell, and core of the NAc, and the medial, central, and basolateral amygdala (mesocorticolimbic areas) that started after the last imposed stress and lasted for 21 days which was correlated with upregulation of µ-opioid receptor in the VTA-NAc pathway (Nikulina et al., 2008). A report also indicates that chronic restraint stress induces higher locomotor activity after amphetamine administration, resulting in cross-sensitization that is associated with enhanced  $\Delta$ FosB expression levels in the NAc of only adult and not adolescent rats (Carneiro De Oliveira et al., 2016).

## A path to relapse: a concise look into possible mechanisms in which ∆FosB begets drug-seeking behaviours and craving and how N-acetylcysteine may rectify these alterations

Human studies are indicative that behavioural changes associated with addiction are exceptionally persistent. Therefore, researchers started figuring out the cellular and molecular mechanisms involved in enduring behavioural abnormalities. In this section, we briefly enumerate potential targets that  $\Delta$ FosB aims at on various levels and determine whether N-acetylcysteine could alter these pathways (Figure 3).

N-acetylcysteine is an accessible, well-tolerated, over-thecounter medicine of low cost with a safe profile regarding adverse effects. It serves as the N-acetylated derivative of the amino acid cysteine and, as such, acts as a prodrug by binding to the cysteineglutamate exchanger. N-acetylcysteine also promotes the efflux of glial glutamate while importing cysteine, resulting in a net increase in the extracellular levels of glutamate in the brain.

## Dendritic arborisation and synaptic plasticity as common targets of different pathways

 $\Delta$ FosB is presumed to influence AMPAR-containing GluR2 receptors and modify glutamatergic signalling by altering the neural excitability of NAc neurons due to overexpression of these receptors. Reduced neural conductance followed by diminished Ca<sup>2+</sup> permeability can affect the excitability of neurons, and prolonged exposure to addictive drugs can change the susceptibility of neurons to rewarding stimuli (Kelz *et al.*, 1999; Nestler, 2001; Nestler *et al.*, 2001). This phenomenon has been shown to



**Figure 3.** Mechanisms of  $\Delta$ FosB involvement in relapse and rectifying actions of N-acetylcysteine.  $\Delta$ FosB contributes to drug-seeking behaviours and relapse through various mechanisms, including enhanced expression of glutamatergic receptors, increasing spine density of medium spiny neurons, modulation of downstream transcription factors [including cyclin-dependent kinase 5 (Cdk5), p35, dynorphin, nuclear factor kappa B (NF-kB), and presumably myocyte enhancer factor 2 (MEF2)] and through epigenetic mechanisms namely by altering histone acetylation and methylation. N-acetylcysteine influences these signaling pathways, holding the potential to reduce drug craving and mitigate the risk of relapse.

exacerbate responses to cues and subsequent increases in craving and relapse (Kelz *et al.*, 1999; Todtenkopf *et al.*, 2006). An additional study exploring the mechanisms underlying resilience and antidepressant response has further affirmed that  $\Delta$ FosB can regulate the expression of GluR2 and exert control over complex behaviours (Vialou *et al.*, 2010). However, in a preclinical study conducted by Conrad et al., a significant connection was established between the presence of increased GluR2-lacking AMPARs in the NAc of rats following extended periods of withdrawal from cocaine, leading to the hypothesis that such an increase may also contribute to enhanced cocaine craving (Conrad *et al.*, 2008).

Short-term expression of  $\Delta$ FosB also leaves different outcomes on D1-type versus D2-type MSNs of the NAc (Grueter et al., 2013). Observations indicate diminished AMPA-related synaptic transmission (reduced excitatory synaptic strength) in D1 receptorexpressing neurons in both the NAc's shell and core via the direct pathway that shapes silent synapses (increased silent synapses onto D1-type). In contrast, an increase in D2-type excitatory transmission through an indirect pathway only on the shell of NAc has been reported (Grueter et al., 2013). Grueter et al. further depicted that morphological changes of the immature dendritic spines are under the influence of direct D1-type MSNs of the NAc and attributed the cocaine-evoked abnormal behaviours to the D1 direct but not D2 indirect pathway, therefore highlighting the celltype and sub-regional-specific manner of  $\Delta$ FosB's mode of action to cocaine-associated behavioural responses (Grueter et al., 2013). In contrast, Lee et al., have demonstrated that  $\Delta$ FosB participates in the short-term induction of increased spine density in both D1- and D2-containing MSNs of NAc (Lee et al., 2006). However,

such an enhanced density of dendritic spines and  $\Delta$ FosB overexpression are maintained and remain stable, specifically in the D1 type MSNs of NAc, even after a month of cocaine withdrawal (Lee *et al.*, 2006). Moreover, elevated levels of  $\Delta$ FosB can enhance the expression of NMDA receptors of the mesocorticolimbic pathway, especially on the MSNs of the NAc, which further leads to long-term potentiation and hijacks the associated memory pathways (Daneff and Jadavji, 2019).

## Transcriptional downstream targets

Evidence has pointed out that  $\Delta$ FosB is one of the primary regulators of transcriptional phenotype changes that occur with repeated consumption of addictive substances that ultimately result in not only addiction-related behavioural responses but also natural rewards (Nestler, 2008; Wallace *et al.*, 2008; Bali and Kenny, 2019).

Studies on transgenic animals overexpressing  $\Delta$ FosB suggested the prominent role of this transcription factor in liability to relapse after the termination of drug consumption and even when the level of  $\Delta$ FosB backs to its normal concentration (Colby *et al.*, 2003; McClung and Nestler, 2003; Nestler, 2008). Findings on the expression profile of  $\Delta$ FosB have delineated that the ongoing predisposition to relapse and drug-taking/seeking behaviours might not directly be affected by  $\Delta$ FosB *per se* (Larson *et al.*, 2010) but instead can trigger several transcriptional cascades that have impacts on the morphology and neural circuits of NAc neurons, thus mediating neural adaptation (Lee *et al.*, 2006; Ang *et al.*, 2008; Maze *et al.*, 2010; Gajewski *et al.*, 2016).

Enhanced expression and accumulation of  $\Delta$ FosB raise levels of both mRNA and protein of Cdk5 and p35, which is regulated by

the AP-1 site on the gene's promoter (Chen *et al.*, 2000; Bibb *et al.*, 2001; Benavides and Bibb, 2004). Cdk5/p35 involves diverse central nervous system processes, including synaptic plasticity, learning, and memory (Takahashi *et al.*, 2022). Cdk5 further dampens D1 dopaminergic signalling, possibly via augmented phosphorylation of dopamine- and cAMP-regulated neuronal phosphoprotein DARPP-32 (PPP1RB) (Bibb *et al.*, 2001; Benavides and Bibb, 2004).

In addition, myocyte enhancer factor 2 (MEF2) has been introduced as another critical regulator of structural and behavioural plasticity and is involved in developing various neuropsychiatric disorders (Pulipparacharuvil *et al.*, 2008; Zhang and Zhao, 2022). Reduction in the striatal level of MEF2 has been implicated in causing increased dendritic spine density after chronic administration of cocaine. This event is induced by the release of cAMP through the activation of D1 receptors that prevents the further activity of calcineurin at the inhibitory Cdk5 site (Pulipparacharuvil *et al.*, 2008). However, the possible correlation between diminished MEF2 and increased expression of  $\Delta$ FosB should be sought.

Additionally, the opioid peptide dynorphin is a target through which  $\Delta$ FosB exerts its behavioural phenotype (Zachariou *et al.*, 2006). It is also shown that prodynorphin, the dynorphin precursor, is a known target for CREB and that chronic consumption of cocaine is associated with CREB-mediated dynorphin expression in NAc (Teague and Nestler, 2021).

Another putative target of  $\Delta$ FosB is another transcription factor named NF- $\kappa$ B. Enhanced expression of NF- $\kappa$ B in the NAc only after chronic but not acute treatment with cocaine has raised the idea that NF- $\kappa$ B may be under the control of  $\Delta$ FosB. NF- $\kappa$ B engages in long-term plasticity and enhances dendritic density as Cdk5 does (Bibb *et al.*, 2001; Ang *et al.*, 2008; Boersma *et al.*, 2011; Dresselhaus *et al.*, 2018), thus contributing to craving and drugseeking behaviours.

### **Epigenetics**

There are emerging lines of evidence that  $\Delta$ FosB might leave its long-lasting effect by epigenetic alterations since studies have signified that even after protracted withdrawal and return of  $\Delta$ FosB's level to normal, the corresponding effects of it still abide (Mews *et al.*, 2018).

 $\Delta$ FosB alters neuronal morphology by targeting histone methyltransferase G9a. Maze et al. have reported that enhanced expression of  $\Delta$ FosB can result in the repression of lysine dimethyltransferase G9a, which further reduces the dimethylation of histone 3 lysine 9 (H3K9) in the NAc during repeated cocaine exposure. Such a downregulated level of G9a and the subsequent decrease in the process of histone methylation leads to dendritic arborisation and an enhanced tendency to reinstate cocaine abuse (Maze *et al.*, 2010).

Acetylation of H3 and H4 histone subtypes at the promoters of plasticity-associated genes, including Fos, has also been shown to be increased following cocaine exposure (Stewart *et al.*, 2021). Furthermore, a recent study demonstrated that inhibition of histone deacetylase results in an increase of  $\Delta$ FosB gene expression in the NAc and medial prefrontal cortex while also reducing reinstatement of morphine-induced conditioned place preference in rats, confirming the role of epigenetic mechanisms, namely histone acetylation, in the adjustment of drug-induced plasticity (Saberian *et al.*, 2021). Promoters of  $\Delta$ FosB and CREB genes involved in glutamate transmission are thought to be

hyperacetylated in the NAc after cocaine administration (Kennedy *et al.*, 2013), and sustained inhibition of histone deacetylase can stimulate G9a (Kennedy *et al.*, 2013; Eagle *et al.*, 2019).  $\Delta$ FosB and CREB can facilitate signalling transmission through enhanced permeability of Ca<sup>2+</sup> that is modulated by histone acetylation (Mews *et al.*, 2018). By using H3.3 histone barcoding of NAc, Wimmer et al. reported an increase in upregulation of the FosB gene in cocaine self-administration mice and the implication of other novel molecular cascades in cocaine-induced neuronal plasticity (Wimmer *et al.*, 2019). Moreover, following administration of amphetamine, histone deacetylase budges to the Fos gene promoter and controls its expression (Torres *et al.*, 2015). Therefore, it should be explored in-depth whether  $\Delta$ FosB can broadly affect histone modification and coding (Eagle *et al.*, 2019).

## N-acetylcysteine and preclinical and clinical studies on relapse to substance abuse

There are comprehensive reviews on preclinical and clinical studies of N-acetylcysteine in substance use disorders and other psychiatric disorders (Dean *et al.*, 2011; Minarini *et al.*, 2017; Smaga *et al.*, 2021a). Here, we only focus on evidence with a direct nexus to relapse/cravings and drug-seeking behaviours.

### **Preclinical studies**

The majority of studies investigating the effect of N-acetylcysteine on relapse or cravings have primarily focused on alcohol and cocaine use. In a preclinical study, N-acetylcysteine was able to attenuate the accumulation of  $\Delta$ FosB in the mPFC, leading to reduced craving and prevention of ethanol-induced neuroadaptions associated with  $\Delta$ FosB in a mouse model of behavioural sensitisation (Morais-Silva *et al.*, 2016). Although, unlike most studies, the authors could not observe an increased  $\Delta$ FosB expression in the NAc (Morais-Silva *et al.*, 2016). Another preclinical report of such an effect was published later, indicating that N-acetylcysteine diminishes ethanol-seeking behaviour to a great extent of 77 percent along with reacquisition after protracted abstinence in rats self-administering ethanol chronically by 78 percent, pointing to the application of N-acetylcysteine as a treatment to prevent relapse (Lebourgeois *et al.*, 2018).

Recently, Fredriksson et al., have also presented evidence that N-acetylcysteine improves impulse control and attenuates the likelihood of relapse in male rats with long-term alcohol consumption (Fredriksson *et al.*, 2023). However, no significant difference was observed in the quantity of alcohol consumed or the motivation to drink (Fredriksson *et al.*, 2023). Using another animal model to evaluate ethanol-relapse drinking behaviour, the alcohol deprivation effect model, N-acetylcysteine was shown to be effective in preventing relapse by reducing the heightened intake of alcohol following a period of abstinence (Cano-Cebrián *et al.*, 2021). The effective dose range of N-acetylcysteine on ethanol in these preclinical studies was between 60 and 120 mg/kg.

Besides alcohol, some preclinical studies have also addressed N-acetylcysteine's impact on cocaine-seeking behaviour. Findings from a study by Amen et al., demonstrated that repeated N-acetylcysteine administration (60 mg/kg for 7 days) resulted in a significant decrease in cocaine-seeking behaviour in rats, and these findings were further validated in the same study through reductions in craving in cocaine-dependent humans as well (Amen *et al.*, 2011). Additionally, findings from another study

have demonstrated that N-acetylcysteine (100 mg/kg) prevented cocaine and alcohol seeking following acute restraint stress (Garcia-Keller *et al.*, 2020). In another study, N-acetylcysteine amide has also been shown to effectively block cocaine-seeking behaviour in rats (Jastrzębska *et al.*, 2016). Moreover, N-acetylcysteine has been demonstrated to prevent cocaine-primed reinstatement, suggesting that this treatment can alter the plasticity-dependent effects of cocaine (Madayag *et al.*, 2007).

### **Clinical trials**

Several clinical studies have also investigated the impact of N-acetylcysteine on craving and substance use relapse in populations with various substance use disorders (Table 1). In a human study involving veterans with both post-traumatic stress disorder (PTSD) and substance use disorders, the administration of N-acetylcysteine (1200 mg twice a day) led to improved craving compared to the placebo (Back *et al.*, 2016). A recent double-blind placebo-controlled trial has also demonstrated that supplementation with N-acetylcysteine (2700 mg daily) resulted in significant benefits on measures of drug craving among treatment-resistant PTSD individuals. However, it did not affect other PTSD symptoms (Kanaan *et al.*, 2023).

There have also been several studies exploring N-acetylcysteine in cocaine use disorder. In a double-blind placebo-controlled trial aiming at evaluating the efficacy of N-acetylcysteine (2400 mg daily) for treating cocaine use disorder, no correlations were found between measures related to relapse (LaRowe et al., 2013). Nevertheless, a subgroup of enrolled patients who were already abstinent before the trial's commencement exhibited a longer duration of time to relapse, indicating that N-acetylcysteine might have a protective role in abstained patients with cocaine use disorder (LaRowe et al., 2013). Findings from the same authors also showed that there were trends for a greater reduction in cocaine withdrawal symptoms and craving within N-acetylcysteine treatment compared to the placebo (LaRowe et al., 2006). In a more recent trial by Woodcock et al., N-acetylcysteine treatment (3600 mg/day for 1 week) suppressed cocaine-seeking behaviour (Woodcock et al., 2021). However, another trial failed to show N-acetylcysteine's effect on craving, number of abstinent days, and days until relapse in cocaine-dependent individuals. Nevertheless, the study showed that N-acetylcysteine was associated with lower positive urine tests, lower cocaine use-related problems and inhibition (Schulte et al., 2018).

Studies on the effects of N-acetylcysteine on methamphetamine use disorder have been inconclusive so far, with one study showing no reduction in craving (McKetin *et al.*, 2021), but another study reporting a decrease in methamphetamine craving (Mousavi *et al.*, 2015). Similarly, trials on cannabis use disorders have been inconsistent, with studies showing improved cannabis abstinence following N-acetylcysteine treatment in adolescents (gray *et al.*, 2012), but not in adults (gray *et al.*, 2017).

In terms of nicotine use disorder, in a pilot randomised placebocontrolled trial, no significant decrease in craving after short-term abstinence (3.5 days) was observed. However, participants receiving a daily dose of 3600 mg N-acetylcysteine reported their initial smoking experience being less rewarding after abstinence. This finding suggests a potential avenue for further research into the viability of N-acetylcysteine as a good candidate for relapse prevention in nicotine use disorder as well (Schmaal *et al.*, 2011). In later studies, while some trials reported no significant outcomes following N-acetylcysteine in nicotine-dependent individuals (Schulte *et al.*, 2017; McClure *et al.*, 2021), several other trials reported that N-acetylcysteine treatment resulted in less craving (Froeliger *et al.*, 2015; Harlivasari *et al.*, 2024), nicotine dependence (Grant *et al.*, 2014), and reduction in cigarettes smoked (Knackstedt *et al.*, 2009; Prado *et al.*, 2015).

When it comes to alcohol use disorder, a recent trial by Morley et al., has shown that N-acetylcysteine reduced the number of drinks but did not affect craving (Morley *et al.*, 2023). Another trial demonstrated that N-acetylcysteine increased the odds of alcohol abstinence, fewer drinks per week, and fewer drinking days per week (Squeglia *et al.*, 2018). However, two other studies showed that N-acetylcysteine did not affect drinking outcomes (Stoops *et al.*, 2020) (Squeglia *et al.*, 2016).

While human clinical results remain inconsistent, two systematic reviews and meta-analyses have concluded the superiority of N-acetylcysteine to placebo in the reduction of cravings among individuals with substance use disorders (Duailibi *et al.*, 2017; Chang *et al.*, 2021). Although these findings are obtained from the pooled analysis of different abused substances, the compelling outcome stimulates further studies to elucidate the specific and nuanced impact of N-acetylcysteine on craving symptoms in individuals with substance use disorders.

# Mechanistic insights into how N-acetylcysteine can affect drug use relapse and craving

There is evidence on how N-acetylcysteine can potentially contribute to decreasing drug use relapse and craving. Here, we provide potential mechanisms for N-acetylcysteine's impact on dendritic arborisation, synaptic plasticity, transcriptional downstream targets, and epigenetics, which offer a possible link with  $\Delta$ FosB-related signalling in drug use relapse and craving (Figure 3).

## *N*-acetylcysteine rectification of altered dendritic arborizations and synaptic plasticity

The ability of N-acetylcysteine to directly and indirectly modulate glutamatergic neurotransmission, which becomes dysregulated post-withdrawal and contributes to drug-seeking behaviours, via interactions with glutamate-transporter type 1 (GLT-1) (Knackstedt et al., 2010), as well as NMDARs and AMPARs (Smaga et al., 2021b), positions it as a promising candidate for substance use relapse prevention. Reissner et al., reported that in a rat model of cocaine relapse, N-acetylcysteine effectively inhibited cue-induced cocaine reinstatement through the engagement of GLT-1 (Reissner et al., 2015). Furthermore, another study also indicated that N-acetylcysteine restores the decrease in GLT-1 levels in both the NAc and dorsal striatum during prolonged but not short cocaine self-administration in rats. This phenomenon was accompanied by an upregulation in the expression of the transcription factor Zif268 (Ducret et al., 2016). Moreover, a recent study by Siemsen et al. demonstrated that heroin self-administration and extinction increased prelimbic cortical astrocyte-synapse proximity and circuit-level adaptations in cortical dendritic spine morphology. At the same time, N-acetylcysteine reversed these adaptations in corticostriatal neurons and astrocytes (Siemsen et al., 2023).

N-acetylcysteine has also been shown to exhibit a dosedependent bidirectional effect on the release of dopamine (Gere-Pászti and Jakus, 2009). At the same time, higher doses of N-acetylcysteine hamper striatal dopamine release. Lower doses

Table 1.	Clinical trials ex	ploring the effe	cts of N-acetylc	ysteine on substa	nce use abstinenc	e, relapse, ar	d craving

Studied population diagnosis	Trial design	N-acetylcysteine dose and duration	Findings	Reference
PTSD and substance use disorder	Double-blind randomised placebo-controlled trial	2400 mg/day for 8 weeks	N-acetylcysteine improved craving compared to the placebo	(Back et al., 2016)
PTSD	Double-blind randomised placebo-controlled trial	2700 mg/day for 12 weeks	N-acetylcysteine improved substance craving duration and resistance, but not other PTSD symptoms compared to the placebo	(Kanaan et al., 2023)
Cocaine use disorder	Double-blind randomised placebo-controlled trial	1200 or 2400 mg/day for 8 weeks	Individuals who were already abstinent before the trial's commencement exhibited a longer duration of time to relapse and lower craving rates in the 2400 mg/day N-acetylcysteine group compared to the placebo	(LaRowe <i>et al.</i> , 2013)
Cocaine use disorder	Double-blind placebo- controlled crossover trial	3600 mg/day for 1 week	N-acetylcysteine suppressed cocaine-seeking behaviour	(Woodcock <i>et al.</i> , 2021)
Cocaine use disorder	Double-blind randomised placebo-controlled trial	2400 mg/day for 25 days	N-acetylcysteine did not affect craving, number of abstinent days and days until relapse. However, N-acetylcysteine was associated with lower positive urine tests, lower cocaine use- related problems and inhibition	(Schulte <i>et al.</i> , 2018)
Cocaine use disorder	Double-blind placebo- controlled crossover trial	2400 mg/day for 3 days	There were trends for a greater reduction in withdrawal symptoms and craving within N- acetylcysteine treatment	(LaRowe <i>et al.</i> , 2006)
Methamphetamine use disorder	Double-blind randomised placebo-controlled trial	2400 mg/day for 12 weeks	No reduction in craving, severity of dependence and withdrawal was seen in the N- acetylcysteine group compared to the placebo	(McKetin <i>et al.</i> , 2021)
Methamphetamine use disorder	Double-blind placebo- controlled crossover trial	600 mg/day for 2 weeks followed by 1200 mg/ day for 2 weeks	N-acetylcysteine resulted in a decrease in methamphetamine craving	(Mousavi <i>et al</i> ., 2015)
Cannabis use disorder	Double-blind randomised placebo-controlled trial	2400 mg/day for 8 weeks	Adolescents receiving N-acetylcysteine had improved cannabis abstinence compared to placebo	(Gray et al., 2012)
Cannabis use disorder	Double-blind randomised placebo-controlled trial	1200 mg/day for 12 weeks	N-acetylcysteine and placebo groups did not differ in cannabis abstinence among adults	(Gray et al., 2017)
Nicotine use disorder	Double-blind randomised placebo-controlled trial	3600 mg/day for 3.5 days	Patients receiving N-acetylcysteine reported their initial smoking experience being less rewarding after abstinence, but no significant effects were seen in craving and withdrawal symptoms	(Schmaal <i>et al</i> ., 2011)
Nicotine use disorder	Double-blind randomised placebo-controlled trial	2400 mg/day for 3.5 days	Smokers in N-acetylcysteine group reported less craving compared to placebo	(Froeliger et al., 2015)
Nicotine use disorder and pathological gambling	Double-blind randomised placebo-controlled trial	1200–3000 mg/day for 12 weeks	Significant benefit of N-acetylcysteine was seen in nicotine dependence scores compared to placebo	(Grant et al., 2014)
Nicotine use disorder	Double-blind randomised placebo-controlled trial	2400 mg/day for 4 weeks	Participants treated with N-acetylcysteine reported a reduction in cigarettes smoked	(Knackstedt <i>et al.</i> , 2009)
Nicotine use disorder	Double-blind randomised placebo-controlled trial	3000 mg/day for 12 weeks	N-acetylcysteine significantly reduced the daily number of cigarettes used and resulted in greater quit rate	(Prado <i>et al.</i> , 2015)
Nicotine use disorder	Double-blind randomised placebo-controlled trial	2400 mg/day for 2 weeks	N-acetylcysteine did not affect craving or withdrawal symptoms	(Schulte et al., 2017)
Nicotine use disorder	Double-blind randomised placebo-controlled trial	2400 mg/day for 4 weeks	N-acetylcysteine group had a higher abstinence rate and lower craving than the placebo group	(Harlivasari <i>et al</i> ., 2024)
Nicotine use disorder	Double-blind randomised placebo-controlled trial	1800 mg/day for 16 weeks	There was no significant difference in smoking outcomes between N-acetylcysteine and placebo groups	(Arancini <i>et al.</i> , 2021)
Nicotine use disorder	Double-blind randomised placebo-controlled trial	2400 mg/day for 8 weeks	No differences between N-acetylcysteine and placebo groups in terms of early abstinence, time to relapse and end-of-treatment abstinence	(McClure <i>et al.</i> , 2021)

#### Table 1. (Continued)

Studied population diagnosis	Trial design	N-acetylcysteine dose and duration	Findings	Reference
Alcohol use disorder	Double-blind randomised placebo-controlled trial	2400 mg/day for 4 weeks	N-acetylcysteine had effects on number of standard drinks per drinking day, but not on craving compared to placebo	(Morley <i>et al.</i> , 2023)
Alcohol use disorder	Double-blind randomised placebo-controlled trial	1200 mg/day or 2400 mg/day for 5 days	N-acetylcysteine did not influence alcohol self- administration or other subjective effects	(Stoops <i>et al.</i> , 2020)
Alcohol use in cannabis- dependent individuals	Double-blind randomised placebo-controlled trial	2400 mg/day for 12 weeks	N-acetylcysteine increased the odds of alcohol abstinence, fewer drinks per week and fewer drinking days per week	(Squeglia <i>et al.</i> , 2018)
Alcohol use in cannabis- dependent individuals	Randomised placebo- controlled trial	2400 mg/day for 8 weeks	N-acetylcysteine did not affect abstinence and binge drinking days compared to the placebo. However, in the N-acetylcysteine group, but not the placebo group, less marijuana use was associated with less alcohol use	(Squeglia et al., 2016)

are associated with an increased release of dopamine in the striatum (Gere-Pászti and Jakus, 2009). Besides, in a primate study, N-acetylcysteine protected against the reduction of striatal dopamine transporter availability, followed by chronic administration of methamphetamine (Hashimoto *et al.*, 2004).

The impacts N-acetylcysteine exerts on dopamine availability and the regulation of NMDAR activity can, in part, be germane to facilitating glutathione production (Dean *et al.*, 2011). Glutathione can then affect the glutamatergic signalling without altering the level of glutamate (Bradlow *et al.*, 2022). Elevated levels of accumbal glutathione in the brains of rats have been reported following treatment with N-acetylcysteine. The increase is believed to result from cell-type specific shifts in glutamatergic inputs to the NAc's MSNs (Zalachoras *et al.*, 2022).

On the other hand, there are studies on the alterations in longterm potentiation (LTP) and long-term depression (LTD) during drug withdrawal or reinstatement. For instance, Qian et al., demonstrated that morphine withdrawal brings about the downregulation of mGluR2/3, impairing NMDA receptor-dependent LTD in the NAc (Qian et al., 2019). Moreover, in a study using a reinstatement animal model of drug-seeking behaviour, it was demonstrated that cocaine-induced metaplasticity impaired the induction of LTP and LTD at the PFC-NAc, a phenomenon linked to relapse vulnerability (Moussawi et al., 2009). Interestingly, Nacetylcysteine not only prevented relapse and cravings but also restored the induction of LTP. This restoration was presumably achieved through indirect stimulation of mGluRs (mGluR2/3 and mGluR5 primarily), possibly associated with the activation of the cysteine-glutamate exchange system (Moussawi et al., 2009). The cysteine-glutamate antiporter regulates glutamate release, which in turn activates presynaptic neuronal mGluR2/3, thereby modulating the vesicular transmission of glutamate (Berk et al., 2013).

Taken together, all these lines of evidence suggest that N-acetylcysteine is a potential candidate to rectify the altered glutamatergic and dopaminergic neurotransmission in individuals vulnerable to relapse and reinstatement. The shared dynamics of N-acetylcysteine's interaction with  $\Delta$ FosB signalling warrant further research to comprehensively understand its potential therapeutic role.

# *N*-acetylcysteine impacts on altered transcriptional downstream targets

N-acetylcysteine can be a modulator of redox hemostasis by mitigating the activity of NF-κB through inhibition of IkappaB kinases (Oka *et al.*, 2000; Farid *et al.*, 2005; Fischer *et al.*, 2006; Mackenzie *et al.*, 2006). AP-1 has also been demonstrated as a target for N-acetylcysteine, where its activity is diminished via the production of glutathione and the suppression of reactive oxygen species generation (Sen and Packer, 1996; Mackenzie *et al.*, 2006; Shi *et al.*, 2017). A recent study has also provided evidence that Nacetylcysteine is also capable of diminishing and normalising the hyperactivity of Cdk5, showcasing therapeutic potential in disorders where the excessive enzymatic activity of Cdk5 is implicated (Saha *et al.*, 2023), including relapse to substance use and reinstatement behaviour.

Considering the significance of these three downstream entities of  $\Delta$ FosB in the pathophysiology of relapse, N-acetylcysteine has the potential to reverse the elevated levels of CREB and Cdk5 induced by the overexpression of AP-1 while also addressing heightened levels of NF- $\kappa$ B and Cdk5, which have established roles in craving and drug-seeking behaviour.

### N-acetylcysteine's impact on epigenetics

Given the role of epigenetics in the pathophysiology of relapse, it is of note to mention that in mammalian cells, histone H3 undergoes S-glutathionylation, introducing glutathione as a novel post-translational participant of the modification of the histone code (García-Giménez *et al.*, 2017). However, glutathione's impact on epigenetic processes goes far beyond H3, and a substantial body of evidence supports the notion that glutathione plays a significant role in epigenetic regulation at various levels (García-Giménez *et al.*, 2017). This includes its influence on DNA methylation, histone post-translational modification, non-coding RNAs, and even modulation of chromatin structure (Cyr and Domann, 2011; García-Giménez *et al.*, 2017)

This regulatory effect of glutathione on epigenetic processes positions N-acetylcysteine, its precursor, as a prospective candidate for potential epigenetic dysregulation influenced by substance use disorders and implicated in the pathophysiology of relapse and cravings. Nevertheless, it is crucial to emphasise that further in-depth explorative and confirmatory studies are needed to assess N-acetylcysteine's efficacy and involvement in this context fully. The establishment of a robust scientific foundation through comprehensive research may help determine whether N-acetylcysteine could act as a potential therapeutic tool for modifying altered epigenetic processes induced by substance use disorders.

## **Concluding remarks**

Relapse and reinstatement to drugs of abuse, even after successfully quitting them, is a deadlock to reaching the ultimately desired treatment goals in substance use disorders. To overcome the relapse, the biological components behind such an unbridled craving should intensively be sought.  $\Delta$ FosB is one of the presumed candidates responsible for morphological and psychobiological alterations in an addicted brain. In specific brain parts,  $\Delta$ FosB can modulate several downstream transcriptional factors, such as NF- $\kappa$ B and Cdk5. It also affects AMPA and NMDA receptors through glutamatergic neurotransmission and controls synaptic plasticity. One other explanation of how  $\Delta$ FosB leaves such permanent effects is epigenetic modifications. Though we have good evidence to rely on, there is much ground to be made up, and further studies are needed to illuminate the role of  $\Delta$ FosB in relapse and craving comprehensively (Question Box).

Knowing the intricate roles and mechanisms behind  $\Delta$ FosB's mode of action in substance use disorders, we might be able to target several upstream and downstream related components to obliterate the associated memory with drugs of abuse and introduce a new treatment strategy to avoid relapse and reinforcement. N-acetylcysteine has demonstrated effectiveness in preventing relapse, reducing craving, and curtailing drugseeking behaviours in both preclinical and clinical studies, although some discrepancies exist. Due to its potential to modulate glutamatergic and dopaminergic neurotransmission, along with its ability to affect downstream signalling transcription factors and pathways altered by  $\Delta$ FosB, N-acetylcysteine holds promise as a potential treatment strategy for preventing relapse to substance use. Nevertheless, a more extensive body of both preclinical and clinical research is warranted to establish its efficacy and unravel the elusive mechanisms underlying its effects. Its well-tolerated nature, safety profile, and accessibility make it an ideal candidate for patients with substance use disorder who are already at risk of toxicity and overdose.

Author contributions. SA drafted the original version of the manuscript and the question box, with input from MI & MS. MI contributed to drafting the manuscript, designed and provided the figures and the table. PHG, RGO, and GW offered critical feedback and contributed to shaping the revised version. SA and MI contributed to drafting the revised version. All authors reviewed the manuscript for the intellectual content and approved the final version for submission.

Funding statement. The authors received no specific funding for this paper.

**Competing interests.** Gregers Wegener is the Editor-in-Chief of *Acta Neuropsychiatrica* at the time of submission but was not involved and actively withdrew during the review and decision process of this manuscript.

### Question box

- Can keeping the NAc's CREB level high, and preventing the CREB's level from declining in the NAc be a potential target to reduce the rate of relapse after reinstatement (by affecting dynorphin activity)?
- Is  $\Delta FosB's$  effects on relapse to substance use sex-specific? What can be the controlling mechanisms?
- How can the induction of  $\Delta\text{FosB}$  in different subtypes of MSNs influence its mode of action?
- Can having the phosphorylation of  $\Delta$ FosB targeted therapeutically reduce the relapse by reducing the half-life of  $\Delta$ FosB?
- Can alteration of ΔFosB's dimerization pattern be of potential therapeutic importance?
- How can CaMKII be selectively modulated in substance use disorders?
- Can modulation of ΔFosB's production through upstream signalling (CREB, SRF, ALK4, PCBP1, etc) be of therapeutic value in relapse to drugs of abuse?
- How significant is the role of NMDARs in relapse and can alteration of long-term potentiation be targeted to reduce the craving and reinstatemennt?
- Is there a possible correlation between diminished MEF2 and increased expression of  $\Delta$ FosB in substance use disorders?
- Can epigenetic alteration of chromatin accessibility be a promising therapeutic target in substance use disorders?
- Do different levels of steroid hormones affect the liability to relapse in substance use disorders by changing chromatin accessibility?
- Is  $\Delta\mathsf{FosB's}$  distinct effect in sexes controlled with sex hormones effect on chromatin remodeling?
- What are the roles of silent synapses in the pathophysiology of relapse and how does  $\Delta$ FosB modulate them?

### References

- Alibhai IN, Green TA, Potashkin JA and Nestler EJ (2007) Regulation of fosB and  $\Delta$ fosB mRNA expression: in vivo and in vitro studies. *Brain Research* **1143**, 22–33. DOI: 10.1016/j.brainres.2007.01.069.
- Amen SL, Piacentine LB, Ahmad ME, Li S-J, Mantsch JR, Risinger RC and Baker DA (2011) Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. *Neuropsychopharmacology* **36**, 871–878.
- Ang E, Chen J, Zagouras P, Magna H, Holland J, Schaeffer E and Nestler EJ (2008) Induction of nuclear factor-κB in nucleus accumbens by chronic cocaine administration. *Journal of Neurochemistry* **79**, 221–224. DOI: 10.1046/j.1471-4159.2001.00563.x.
- Arancini L, Mohebbi M, Berk M, Dean OM, Bortolasci CC, Spolding B, Zazula R and Dodd S (2021) A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking. *European Neuropsychopharmacology* 53, 120–126.
- Back SE, McCauley JL, Korte KJ, Gros DF, Leavitt V, Gray KM, Hamner MB, DeSantis SM, Malcolm R and Brady KT (2016) A double-blind, randomized, controlled pilot trial of N-acetylcysteine in veterans with posttraumatic stress disorder and substance use disorders. J Clin Psychiatry 77, 1–2406.
- Bali P and Kenny PJ (2019) Transcriptional mechanisms of drug addiction. *Dialogues in Clinical Neuroscience* **21**(4), 379–387.
- Becker JB and Koob GF (2016) Sex differences in animal models: focus on addiction. *Pharmacological Reviews* **68**, 242–263.
- Benavides DR and Bibb JA (2004) Role of Cdk5 in drug abuse and plasticity. Annals of the New York Academy of Sciences, **1025**(1), 335–344. DOI: 10. 1196/annals.1316.041.
- Berk M, Malhi GS, Gray LJ and Dean OM (2013) The promise of N-acetylcysteine in neuropsychiatry. *Trends in Pharmacological Sciences* 34, 167–177.
- Bibb JA, Chen J, Taylor JR, Svenningsson P, Nishi A, Snyder GL, Yan Z, Sagawa ZK, Ouimet CC, Nairn AC, Nestler EJ and Greengard P (2001) Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. *Nature* **410**, 376–380. DOI: 10.1038/35066591.

- Boersma MCH, Dresselhaus EC, de Biase LM, Mihalas AB, Bergles DE and Meffert MK (2011) A requirement for nuclear factor-κB in developmental and plasticity-associated synaptogenesis. *Journal of Neuroscience* **31**, 5414–5425. DOI: 10.1523/JNEUROSCI.2456-10.2011.
- Bradlow RCJ, Berk M, Kalivas PW, Back SE and Kanaan RA (2022) The potential of N-acetyl-L-cysteine (NAC) in the treatment of psychiatric disorders. CNS Drugs 36, 451–482.
- Bryant CD and Yazdani N (2016) RNA-binding proteins, neural development and the addictions. *Genes Brain and Behavior* 15, 169–186. DOI: 10.1111/ gbb.12273.
- Cadet JL (2021) Sex in the nucleus accumbens: ΔFosB, addiction, and affective states. *Biological Psychiatry* 90, 508–510.
- Cano-Cebrián MJ, Fernández-Rodríguez S, Hipólito L, Granero L, Polache A and Zornoza T (2021) Efficacy of N-acetylcysteine in the prevention of alcohol relapse-like drinking: study in long-term ethanol-experienced male rats. *Journal of Neuroscience Research* 99, 638–648.
- Carle TL, Ohnishi YN, Ohnishi YH, Alibhai IN, Wilkinson MB, Kumar A and Nestler EJ (2007) Proteasome-dependent and -independent mechanisms for fosB destabilization: identification of fosB degron domains and implications for ΔFosB stability. *European Journal of Neuroscience* 25, 3009– 3019. DOI: 10.1111/j.1460-9568.2007.05575.x.
- Carneiro De Oliveira PE, Leão RM, Bianchi PC, Marin MT, Da Silva Planeta C and Cruz FC (2016) Stress-induced locomotor sensitization to amphetamine in adult, but not in adolescent rats, is associated with increased expression of  $\Delta$ FosB in the nucleus accumbens. *Frontiers in Behavioral Neuroscience* **10**, 173. DOI: 10.3389/FNBEH.2016.00173/ BIBTEX.
- Chang C-T, Hsieh P-J, Lee H-C, Lo C-H, Tam K-W and Loh E-W (2021) Effectiveness of N-acetylcysteine in treating clinical symptoms of substance abuse and dependence: a meta-analysis of randomized controlled trials. *Clinical Psychopharmacology and Neuroscience* 19, 282–293.
- Chapp AD, Nwakama CA, Jagtap PP, Phan C-MH, Thomas MJ and Mermelstein PG (2024) Fundamental sex differences in cocaine-induced plasticity of dopamine D1 receptor-and D2 receptor-expressing medium spiny neurons in the mouse nucleus accumbens shell. *Biological Psychiatry Global Open Science* 4, 100295.
- Chen J, Zhang Y, Kelz MB, Steffen C, Ang ES, Zeng L and Nestler EJ (2000) Induction of cyclin-dependent kinase 5 in the hippocampus by chronic electroconvulsive seizures: role of  $\Delta$ FosB. *Journal of Neuroscience* **20**, 8965–8971. DOI: 10.1523/jneurosci.20-24-08965.2000.
- Colby CR, Whisler K, Steffen C, Nestler EJ and Self DW (2003) Striatal cell type-specific overexpression of ΔFosB enhances incentive for cocaine. *Journal of Neuroscience* 23, 2488–2493. DOI: 10.1523/jneurosci.23-06-02488.2003.
- Conrad KL, Tseng KY, Uejima JL, Reimers JM, Heng L-J, Shaham Y, Marinelli M and Wolf ME (2008) Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. *Nature* 454, 118–121.
- Cyr AR and Domann FE (2011) The redox basis of epigenetic modifications: from mechanisms to functional consequences. *Antioxid Redox Signal* 15, 551–589.
- Daiwile AP, Jayanthi S and Cadet JL (2022a) Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: potential therapeutic impacts. *Neuroscience & Biobehavioral Reviews* 137, 104674.
- Daiwile AP, Sullivan P, Jayanthi S, Goldstein DS and Cadet JL (2022b) Sexspecific alterations in dopamine metabolism in the brain after methamphetamine self-administration. *International Journal of Molecular Sciences* 23, 4353.
- Daneff M and Jadavji N (2019) The role of synaptic plasticity in the pathophysiology of cocaine addiction. *Journal of Young Investigators* 37, 33–38. DOI: 10.22186/jyi.37.4.33-38.
- Dean O, Giorlando F and Berk M (2011) N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. *Journal of Psychiatry and Neuroscience* **36**, 78–86.
- **Dresselhaus EC, Boersma MCH and Meffert MK** (2018) Targeting of NF-κB to dendritic spines is required for synaptic signaling and spine development.

*Journal of Neuroscience* **38**, 4093–4103. DOI: 10.1523/JNEUROSCI.2663-16. 2018.

- Duailibi MS, Cordeiro Q, Brietzke E, Ribeiro M, LaRowe S, Berk M and Trevizol AP (2017) N-acetylcysteine in the treatment of craving in substance use disorders: systematic review and meta-analysis. *The American Journal on Addictions* 26, 660–666.
- Ducret E, Puaud M, Lacoste J, Belin-Rauscent A, Fouyssac M, Dugast E, Murray JE, Everitt BJ, Houeto J-L and Belin D (2016) N-acetylcysteine facilitates self-imposed abstinence after escalation of cocaine intake. *Biological Psychiatry* 80, 226–234.
- Eagle A, Al Masraf B and Robison AJ (2019) Transcriptional and epigenetic regulation of reward circuitry in drug addiction. In Mary T (ed), Neural Mechanisms of Addiction. Cambridge: Academic Press, pp. 23–34. DOI: 10. 1016/b978-0-12-812202-0.00003-8.
- Farid M, Reid MB, Li Y-P, Gerken E and Durham WJ (2005) Effects of dietary curcumin or N-acetylcysteine on NF-κB activity and contractile performance in ambulatory and unloaded murine soleus. *Nutrition & Metabolism* **2**, 1–8.
- Fischer UM, Antonyan A, Bloch W and Mehlhorn U (2006) Impact of antioxidative treatment on nuclear factor kappa-B regulation during myocardial ischemia-reperfusion. *Interactive CardioVascular and Thoracic* Surgery 5, 531–535.
- Fredriksson I, Jayaram-Lindström N, Kalivas PW, Melas PA and Steensland P (2023) N-acetylcysteine improves impulse control and attenuates relapselike alcohol intake in long-term drinking rats. *Behavioural Brain Research* 436, 114089.
- Froeliger B, McConnell PA, Stankeviciute N, McClure EA, Kalivas PW and Gray KM (2015) The effects of N-acetylcysteine on frontostriatal restingstate functional connectivity, withdrawal symptoms and smoking abstinence: a double-blind, placebo-controlled fMRI pilot study. Drug and Alcohol Dependence 156, 234–242.
- Gajewski PA, Turecki G and Robison AJ (2016) Differential expression of FosB proteins and potential target genes in select brain regions of addiction and depression patients. *PLoS One* 11, e0160355. DOI: 10.1371/journal.pone.
- García-Giménez JL, Roma-Mateo C, Perez-Machado G, Peiro-Chova L and Pallardó FV (2017) Role of glutathione in the regulation of epigenetic mechanisms in disease. *Free Radical Biology and Medicine* 112, 36–48.
- Garcia-Keller C, Smiley C, Monforton C, Melton S, Kalivas PW and Gass J (2020) N-acetylcysteine treatment during acute stress prevents stressinduced augmentation of addictive drug use and relapse. *Addiction Biology* 25, e12798.
- Gere-Pászti E and Jakus J (2009) The effect of N-acetylcysteine on amphetamine-mediated dopamine release in rat brain striatal slices by ion-pair reversed-phase high performance liquid chromatography. *Biomedical Chromatography* 23, 658–664.
- Goeders NE (2003) The impact of stress on addiction. *European Neuropsychopharmacology* **13**, 435–441. DOI: 10.1016/J.EURONEURO. 2003.08.004.
- Goodman J and Packard MG (2016) Memory systems and the addicted brain. *Frontiers in Psychiatry* 7, 24. DOI: 10.3389/fpsyt.2016.00024.
- Grant JE, Odlaug BL, Chamberlain SR, Potenza MN, Schreiber LRN, Donahue CB and Kim SW (2014) A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. *The Journal of Clinical Psychiatry* 75, 39–45. DOI: 10.4088/JCP.13M08411.
- Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, McRae-Clark AL and Brady KT (2012) A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. *American Journal of Psychiatry* 169, 805–812. DOI: 10.1176/APPI.AJP.2012. 12010055/ASSET/IMAGES/LARGE/AJP.169.8.805.F003.JPEG.
- Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A and King JS (2017) A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. *Drug and Alcohol Dependence* 177, 249–257. DOI: 10.1016/J.DRUGALCDEP.2017.04.020.
- **Grueter BA, Robison AJ, Neve RL, Nestler EJ and Malenka RC** (2013) δFosB differentially modulates nucleus accumbens direct and indirect pathway

function. *Proceedings of the National Academy of Sciences* **110**, 1923–1928. DOI: 10.1073/pnas.1221742110.

- Harlivasari A, Susanto A, Taufik F and Cureus TG- (2024, undefined, 2024) The role of twice-daily N-acetylcysteine (NAC) 2400 mg in smoking cessation: a randomized, placebo-controlled trial in Indonesia, Cureus.comAD harlivasari, AD Susanto, FF Taufik, TT ginting, ADA Susanto sr, FF Taufik, T gintingCureus, 2024 DOI: 10.7759/cureus.54322.
- Hashimoto K, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Shimizu E and Iyo M (2004) Effects of N-acetyl-l-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine. *Annals of the New York Academy of Sciences* 1025, 231–235.
- Jastrzębska J, Frankowska M, Filip M and Atlas D (2016) N-acetylcysteine amide (AD4) reduces cocaine-induced reinstatement. *Psychopharmacology* (*Berl*) 233, 3437–3448.
- Kanaan RA, Oliver G, Dharan A, Sendi S, Maier A, Mohebbi M, Ng C, Back SE, Kalivas P and Berk M (2023) A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial of adjunctive N-acetylcysteine for treatment-resistant PTSD. *Psychiatry Research* 327, 115398.
- Kelz MB, Chen J, Carlezon WA, Whisler K, Gilden L, Beckmann AM, Steffen C, Zhang YJ, Marotti L, Self DW, Tkatch T, Baranauskas G, Surmeler DJ, Neve RL, Duman RS, Picciotto MR and Nestler EJ (1999) Expression of the transcription factor ΔFosB in the brain controls sensitivity to cocaine. *Nature* **401**, 272–276. DOI: 10.1038/45790.
- Kelz MB and Nestler EJ (2000) ΔFosB: a molecular switch underlying longterm neural plasticity. *Current Opinion in Neurology* 13, 715–720. DOI: 10.1097/00019052-200012000-00017.
- Kennedy PJ, Feng J, Robison AJ, Maze I, Badimon A, Mouzon E, Chaudhury D, Damez-Werno DM, Haggarty SJ, Han MH, Bassel-Duby R, Olson EN and Nestler EJ (2013) Class i HDAC inhibition blocks cocaine-induced plasticity by targeted changes in histone methylation. *Nature Neuroscience* 16, 434–440. DOI: 10.1038/nn.3354.
- Knackstedt LA, LaRowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S, Markou A and Kalivas PW (2009) The role of cystine-glutamate exchange in nicotine dependence in rats and humans. *Biological Psychiatry* 65, 841–845. DOI: 10.1016/J.BIOPSYCH.2008.10.040.
- Knackstedt LA, Melendez RI and Kalivas PW (2010) Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. *Biological Psychiatry* 67, 81–84.
- Krapacher FA, Fernández-Suárez D, Andersson A, Carrier-Ruiz A and Ibáñez CF (2022) Convergent dopamine and ALK4 signaling to PCBP1 controls FosB alternative splicing and cocaine behavioral sensitization. *The EMBO Journal* 41, 10721.
- Lardner CK, van der Zee Y, Estill MS, Kronman HG, Salery M, Cunningham AM, Godino A, Parise EM, Kim JH and Neve RL (2021) Gene-targeted, CREB-mediated induction of  $\Delta$ FosB controls distinct downstream transcriptional patterns within D1 and D2 medium spiny neurons. *Biological Psychiatry* **90**, 540–549.
- LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN and Malcolm RJ (2013) A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. *The American Journal on Addictions* 22, 443–452.
- LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, Saladin M, McRae A and Brady K (2006) Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. *American Journal on Addictions* 15, 105–110. DOI: 10.1080/10550490500419169.
- Larson EB, Akkentli F, Edwards S, Graham DL, Simmons DL, Alibhai IN, Nestler EJ and Self DW (2010) Striatal regulation of ΔFosB, FosB, and cFos during cocaine self-administration and withdrawal. *Journal of Neurochemistry* 115, 112–122. DOI: 10.1111/j.1471-4159.2010.06907.x.
- Lebourgeois S, González-Marín MC, Jeanblanc J, Naassila M and Vilpoux C (2018) Effect of N-acetylcysteine on motivation, seeking and relapse to ethanol self-administration. *Addiction Biology* 23, 643–652.
- Lee KW, Kim Y, Kim AM, Helmin K, Nairn AC and Greengard P (2006) Cocaine-induced dendritic spine formation in D1 and D2 dopamine receptor-containing medium spiny neurons in nucleus accumbens. *Proceedings of the National Academy of Sciences* **103**, 3399–3404. DOI: 10.1073/pnas.0511244103.

- Lobo MK, Zaman S, Damez-Werno DM, Koo JW, Bagot RC, DiNieri JA, Nugent A, Finkel E, Chaudhury D and Chandra R (2013a) ΔFosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli. *Journal of Neuroscience* **33**, 18381–18395.
- Lobo MK, Zaman S, Damez-Werno DM, Koo JW, Bagot RC, DiNieri JA, Nugent A, Finkel E, Chaudhury D and Chandra R (2013b) ΔFosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli. *Journal of Neuroscience* **33**, 18381–18395.
- Loganathan K and Ho ETW (2021) Value, drug addiction and the brain. *Addictive Behaviors* **116**, 106816.
- Lynch WJ, Nicholson KL, Dance ME, Morgan RW and Foley PL (2010) Animal models of substance abuse and addiction: implications for science, animal welfare, and society. *Comparative Medicine* **60**(3), 177–188.
- Mackenzie GG, Zago MP, Erlejman AG, Aimo L, Keen CL and Oteiza PI (2006) α-lipoic acid and N-acetyl cysteine prevent zinc deficiency-induced activation of NF- $\kappa$ B and AP-1 transcription factors in human neuroblastoma IMR-32 cells. *Free Radical Research* **40**, 75–84.
- Madayag A, Lobner D, Kau KS, Mantsch JR, Abdulhameed O, Hearing M, Grier MD and Baker DA (2007) Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. *The Journal of Neuroscience* 27, 13968–13976. DOI: 10.1523/JNEUROSCI.2808-07.2007.
- Maze I, Covingtoni HE, Dietz DM, Laplant Q, Renthal W, Russo SJ, Mechanic M, Mouzon E, Neve RL, Haggarty SJ, Ren Y, Sampath SC, Hurd YL, Greengard P, Tarakhovsky A, Schaefer A and Nestler EJ (2010) Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. *Science* 327(5962), 213–216. DOI: 10.1126/science.1179438.
- McClung CA and Nestler EJ (2003) Regulation of gene expression and cocaine reward by CREB and ΔFosB. *Nature Neuroscience* **6**, 1208–1215. DOI: 10.1038/nn1143.
- McClure EA, Wahlquist AE and Tomko RL (2021) Evaluating Nacetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. *Drug and Alcohol Dependence* 225, 108815.
- McKetin R, Dean OM, Turner A, Kelly PJ, Quinn B, Lubman DI, Dietze P, Carter G, Higgs P and Sinclair B (2021) N-acetylcysteine (NAC) for methamphetamine dependence: a randomised controlled trial. *EClinicalMedicine* 38.
- Mews P, Walker DM and Nestler EJ (2018) Epigenetic priming in drug addiction. Cold Spring Harbor Symposia on Quantitative Biology 83, 131–139. DOI: 10.1101/sqb.2018.83.037663.
- Milton AL and Everitt BJ (2012) The persistence of maladaptive memory: addiction, drug memories and anti-relapse treatments. *Neuroscience & Biobehavioral Reviews* 36, 1119–1139. DOI: 10.1016/j.neubiorev.2012.01.002.
- Minarini A, Ferrari S, Galletti M, Giambalvo N, Perrone D, Rioli G and Galeazzi GM (2017) N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. *Expert Opinion on Drug Metabolism & Toxicology* 13, 279–292.
- Morais-Silva G, Alves GC and Marin MT (2016) N-acetylcysteine treatment blocks the development of ethanol-induced behavioural sensitization and related  $\Delta$ FosB alterations. *Neuropharmacology* **110**, 135–142.
- Morley KC, Peruch S, Adams C, Towers E, Tremonti C, Watt J, Jamshidil N and Haber PS (2023) N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial. *Alcohol and Alcoholism* 58, 553–560.
- Mousavi SG, Salehi M, Peykanpour M, Sichani NK and Maracy M (2015) The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study. *Archives of Iranian Medicine* **18**, 28–33.
- Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A and Kalivas PW (2009) N-acetylcysteine reverses cocaine-induced metaplasticity. *Nature Neuroscience* 12, 182–189.
- Muschamp JW and Carlezon WA (2013) Roles of nucleus accumbens CREB and dynorphin in dysregulation of motivation. *Cold Spring Harbor Perspectives in Medicine* **3**, a012005. DOI: 10.1101/cshperspect.a012005.
- **Nestler EJ** (2012) Transcriptional mechanisms of drug addiction. *Clinical Psychopharmacology and Neuroscience* **10**, 136–143. DOI: 10.9758/cpn.2012. 10.3.136.

- Nestler EJ (2008) Transcriptional mechanisms of addiction: Role of ΔFosB, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 363(1507), 3245–3255. DOI 10.1098/rstb.2008.0067.
- Nestler EJ (2005) Is there a common molecular pathway for addiction ? *Nature Neuroscience* 8, 1445–1449. DOI: 10.1038/nn1578.
- Nestler EJ (2001) Molecular neurobiology of addiction. *American Journal on Addictions* **10**, 201–217. DOI: 10.1080/105504901750532094.
- Nestler EJ, Barrot M and Self DW (2001) ΔFosB: A sustained molecular switch for addiction. Proceedings of the National Academy of Sciences 98, 11042–11046. DOI: 10.1073/pnas.191352698 1046.
- Nikulina EM, Arrillaga-Romany I, Miczek KA and Hammer RP (2008) Longlasting alteration in mesocorticolimbic structures after repeated social defeat stress in rats: time course of μ-opioid receptor mRNA and FosB/ΔFosB immunoreactivity. *European Journal of Neuroscience* 27, 2272–2284. DOI: 10.1111/J.1460-9568.2008.06176.X.
- Oka S, Kamata H, Kamata K, Yagisawa H and Hirata H (2000) N-acetylcysteine suppresses TNF-induced NF-κB activation through inhibition of IκB kinases. *FEBS Letters* **472**, 196–202.
- Olsen CM (2011) Natural rewards, neuroplasticity, and non-drug addictions. Neuropharmacology 61, 1109–1122. DOI: 10.1016/j.neuropharm.2011.03.010
- Perrotti LI, Hadeishi Y, Ulery PG, Barrot M, Monteggia L, Duman RS and Nestler EJ (2004) Induction of ΔFosB in reward-related brain structures after chronic stress. *Journal of Neuroscience* 24, 10594–10602. DOI: 10.1523/ JNEUROSCI.2542-04.2004.
- Perrotti LI, Weaver RR, Robison B, Renthal W, Maze I, Yazdani S, Elmore RG, Knapp DJ, Selley DE, Martin BR, Sim-Selley L, Bachtell RK, Self DW and Nestler EJ (2008) Distinct patterns of ΔFosB induction in brain by drugs of abuse. *Synapse* **62**, 358–369. DOI: 10.1002/syn.20500.
- Prado E, Maes M, Piccoli LG, Baracat M, Barbosa DS, Franco O, Dodd S, Berk M and Nunes SOV (2015) N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study. *Redox Report* 20, 215–222. DOI: 10.1179/ 1351000215Y.0000000004.
- Pulipparacharuvil S, Renthal W, Hale CF, Taniguchi M, Xiao G, Kumar A, Russo SJ, Sikder D, Dewey CM, Davis MM, Greengard P, Nairn AC, Nestler EJ and Cowan CW (2008) Cocaine regulates MEF2 to control synaptic and behavioral plasticity. *Neuron* 59, 621–633. DOI: 10.1016/j.neu ron.2008.06.020.
- Qian Z, Wu X, Qiao Y, Shi M, Liu Z, Ren W, Han J and Zheng Q (2019) Downregulation of mGluR2/3 receptors during morphine withdrawal in rats impairs mGluR2/3-and NMDA receptor-dependent long-term depression in the nucleus accumbens. *Neuroscience Letters* **690**, 76–82.
- Reissner KJ, Gipson CD, Tran PK, Knackstedt LA, Scofield MD and Kalivas PW (2015) Glutamate transporter GLT-1 mediates N-acetylcysteine inhibition of cocaine reinstatement. *Addiction Biology* 20, 316–323.
- Robinson TE and Kolb B (1997) Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. *Journal of Neuroscience* 17, 8491–8497. DOI: 10.1523/ jneurosci.17-21-08491.1997.
- Robison AJ, Vialou V, Mazei-Robison M, Feng J, Kourrich S, Collins M, Wee S, Koob G, Turecki G, Neve R, Thomas M and Nestler EJ (2013) Behavioral and structural responses to chronic cocaine require a feedforward loop involving  $\Delta$  FosB and calcium/ calmodulin-dependent protein kinase II in the nucleus accumbens shell. *Journal of Neuroscience* **33**, 4295–4307. DOI: 10.1523/JNEUROSCI.5192-12.2013.
- Saberian H, Taei AA, Torkaman-Boutorabi A, Riahi E, Aminyavari S, Naghizadeh A and Farahmandfar M (2021) Effect of histone acetylation on maintenance and reinstatement of morphine-induced conditioned place preference and  $\Delta$ FosB expression in the nucleus accumbens and prefrontal cortex of male rats. *Behavioural Brain Research* **414**, 113477.
- Saha D, Paul S, Gaharwar U, Priya A, Neog A, Singh A and Bk B (2023) Cdk5mediated brain unfolded protein response upregulation associated with cognitive impairments in Type 2 Diabetes and ameliorative action of NAC. *ACS Chemical Neuroscience* **14**, 2761–2774.
- Salaya-Velazquez NF, López-Muciño LA, Mejía-Chávez S, Sánchez-Aparicio P, Domínguez-Guadarrama AA and Venebra-Muñoz A (2020) Anandamide and sucralose change ΔFosB expression in the reward system. *Neuroreport* 31, 240–244. DOI: 10.1097/WNR.000000000001400.

- Scalize Hirata RY, dos Santos TB, de Andrade JS, Le Sueur Maluf L, Antunes HKM, Britto LRG, Céspedes IC and de Barros Viana M (2019) Chronic corticosterone increases ΔFOSB and CRFR1 immunoreactivity in brain regions that modulate aversive conditioning. *Behavioural Brain Research* 356, 107–119. DOI: 10.1016/j.bbr.2018.08.011.
- Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW and van den Brink W (2011) Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. *European Addiction Research* 17, 211–216.
- Schulte MHJ, Goudriaan AE, Kaag AM, Kooi DP, Van Den Brink W, Wiers RW and Schmaal L (2017) The effect of N-acetylcysteine on brain glutamate and gamma-aminobutyric acid concentrations and on smoking cessation: a randomized, double-blind, placebo-controlled trial. *Journal of Psychopharmacology* **31**, 1377–1379.
- Schulte MHJ, Wiers RW, Boendermaker WJ, Goudriaan AE, van den Brink W, van Deursen DS, Friese M, Brede E and Waters AJ (2018) The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and ecological momentary assessment. Addictive Behaviors 83, 79–86.
- Seltenhammer MH, Resch U, Stichenwirth M, Seigner J, Reisinger CM, Vycudilik C and W (2016) Accumulation of highly stable ΔFosB-isoforms and its targets inside the reward system of chronic drug abusers - a source of dependence-memory and high relapse rate? *Journal of Addiction Research & Therapy* 7, 1–8. DOI: 10.4172/2155-6105.1000297.
- Sen CK and Packer L (1996) Antioxidant and redox regulation of gene transcription. The FASEB journal 10, 709–720.
- Shi H, Gu Y, Xie Z, Zhou QI, Mao G, Lin X, Liu K, Liu Y, Zou B and Zhao J (2017) Mechanism of N-acetyl-cysteine inhibition on the cytotoxicity induced by titanium dioxide nanoparticles in JB6 cells transfected with activator protein-1. *Experimental and Therapeutic Medicine* 13, 3549–3554.
- Siemsen BM, Denton AR, Parrila-Carrero J, Hooker KN, Carpenter EA, Prescot ME, Brock AG, Westphal AM, Leath M-N and McFaddin JA (2023) Heroin self-administration and extinction increase prelimbic cortical astrocyte-synapse proximity and alter dendritic spine morphometrics that are reversed by N-acetylcysteine. *Cells* 12, 1812.
- Silva RJM, Galinato MH and Mandyam C (2016) Role of hippocampal neurogenesis in drug addiction. *The FASEB Journal* **30**, 518 4–518 4. DOI: 10.1096/fasebj.30.1\_supplement.518.4.
- Sinha R (2012) How does stress lead to risk of alcohol relapse? *Alcohol Research: Current Reviews* 34, 432–440.
- Sinha R (2008) Chronic stress, drug use, and vulnerability to addiction. Annals of the New York Academy of Sciences 1141, 105–130. DOI: 10.1196/ ANNALS.1441.030.
- Smaga I, Frankowska M and Filip M (2021a) N-acetylcysteine in substance use disorder: a lesson from preclinical and clinical research. *Pharmacological Reports* 73, 1205–1219.
- Smaga I, Frankowska M and Filip M (2021b) N-acetylcysteine as a new prominent approach for treating psychiatric disorders. *British Journal of Pharmacology* 178, 2569–2594.
- Spiga S, Mulas G, Piras F and Diana M (2014) The "addicted" spine. Frontiers in Neuroanatomy 8(OCT), 112491. DOI: 10.3389/fnana.2014.00110.
- Squeglia LM, Baker NL, McClure EA, Tomko RL, Adisetiyo V and Gray KM (2016) Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addictive Behaviors 63, 172–177.
- Squeglia LM, Tomko RL, Baker NL, McClure EA, Book GA and Gray KM (2018) The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. *Drug and Alcohol Dependence* 185, 17–22.
- Stewart AF, Fulton SL and Maze I (2021) Epigenetics of drug addiction. Cold Spring Harbor Perspectives in Medicine 11(7), a040253. DOI: 10.1101/ CSHPERSPECT.A040253.
- Stoops WW, Strickland JC, Hays LR, Rayapati AO, Lile JA and Rush CR (2020) Influence of n-acetylcysteine maintenance on the pharmacodynamic effects of oral ethanol. *Pharmacology Biochemistry and Behavior* 198, 173037.
- Takahashi M, Nakabayashi T, Mita N, Jin X, Aikawa Y, Sasamoto K, Miyoshi G, Miyata M, Inoue T and Ohshima T (2022) Involvement of Cdk5 activating subunit p35 in synaptic plasticity in excitatory and inhibitory neurons. *Molecular Brain* 15, 37. DOI: 10.1186/s13041-022-00922-x.

- Teague CD and Nestler EJ (2021) Key transcription factors mediating cocaineinduced plasticity in the nucleus accumbens. *Molecular Psychiatry* 1–23,
- Todtenkopf MS, Parsegian A, Naydenov A, Neve RL, Konradi C and Carlezon WA (2006) Brain reward regulated by AMPA receptor subunits in nucleus accumbens shell. *Journal of Neuroscience* 26, 11665–11661. DOI: 10.1523/JNEUROSCI.3070-06.2006.
- Torres OV, Mccoy MT, Ladenheim B, Jayanthi S, Brannock C, Tulloch I, Krasnova IN and Cadet JL (2015) CAMKII-conditional deletion of histone deacetylase 2 potentiates acute methamphetamine-induced expression of immediate early genes in the mouse nucleus accumbens. *Scientific Reports* 5, 1–11. DOI: 10.1038/srep13396.
- Ulery PG, Rudenko G and Nestler EJ (2006) Regulation of ΔFosB stability by phosphorylation. *Journal of Neuroscience* 26, 5131–5142. DOI: 10.1523/ JNEUROSCI.4970-05.2006.
- Vialou V, Feng J, Robison AJ, Ku SM, Ferguson D, Scobie KN, Mazei-Robison MS, Mouzon E and Nestler EJ (2012) Serum response factor and cAMP response element binding protein are both required for cocaine induction of  $\Delta$ FosB. *Journal of Neuroscience* **32**, 7577–7584. DOI: 10.1523/ JNEUROSCI.1381-12.2012.
- Vialou V, Robison AJ, Laplant QC, Covington HE, Dietz DM, Ohnishi YN, Mouzon E, Rush AJ, Watts EL, Wallace DL, Îiguez SD, Ohnishi YH, Steiner MA, Warren BL, Krishnan V, Bolãos CA, Neve RL, Ghose S, Berton O, Tamminga CA and Nestler EJ (2010) ΔfosB in brain reward circuits mediates resilience to stress and antidepressant responses. *Nature Neuroscience* 13, 745–752. DOI: 10.1038/nn.2551.
- Volkow ND and Morales M (2015) The brain on drugs: from reward to addiction. *Cell* 162, 712–725. DOI: 10.1016/j.cell.2015.07.046
- Wallace DL, Vialou V, Rios L, Carle-Florence TL, Chakravarty S, Kumar A, Graham DL, Green TA, Kirk A, Iñiguez SD, Perrotti LI, Barrot M, DiLeone RJ, Nestler EJ and Bolaños-Guzmán CA (2008) The influence of ΔfosB in the nucleus accumbens on natural reward-related behavior. *Journal* of Neuroscience 28, 10272–10277. DOI: 10.1523/JNEUROSCI.1531-08.2008.
- Wang Y, Cesena TI, Ohnishi Y, Burger-Caplan R, Lam V, Kirchhoff PD, Larsen SD, Larsen MJ, Nestler EJ and Rudenko G (2012) Small molecule screening identifies regulators of the transcription factor  $\Delta$ fosB. ACS Chemical Neuroscience 3, 546–556. DOI: 10.1021/cn3000235.
- Wassum KM and Izquierdo A (2015) The basolateral amygdala in reward learning and addiction. *Neuroscience & Biobehavioral Reviews* 57, 271–283. DOI: 10.1016/j.neubiorev.2015.08.017.
- Wen D, Hui R, Liu Y, Luo Y, Wang J, Shen X, Xie B, Yu F, Cong B and Ma C (2020) Molecular hydrogen attenuates methamphetamine-induced behavioral sensitization and activation of ERK-ΔFosB signaling in the mouse

nucleus accumbens. Progress in Neuro-Psychopharmacology & Biological Psychiatry 97, 109781. DOI: 10.1016/j.pnpbp.2019.109781.

- Willuhn I, Wanat MJ, Clark JJ and Phillips PEM (2010) Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse. *Current Topics in Behavioral Neurosciences* 3, 29–71. DOI: 10.1007/7854\_ 2009\_27
- Wimmer ME, Fant B, Swinford-Jackson SE, Testino A, Van Nest D, Abel T and Pierce RC (2019) H3. 3 barcoding of nucleus accumbens transcriptional activity identifies novel molecular cascades associated with cocaine selfadministration in mice. *Journal of Neuroscience* 39, 5247–5254.
- Woodcock EA, Lundahl LH, Khatib D, Stanley JA and Greenwald MK (2021) N-acetylcysteine reduces cocaine-seeking behavior and anterior cingulate glutamate/glutamine levels among cocaine-dependent individuals. Addiction Biology 26, e12900. DOI: 10.1111/ADB.
- Yeh S-Y, Estill M, Lardner CK, Browne CJ, Minier-Toribio A, Futamura R, Beach K, McManus CA, Xu S and Zhang S (2023) Cell type-specific whole-genome landscape of ΔFOSB binding in the nucleus accumbens after chronic cocaine exposure. *Biological Psychiatry* **94**, 367–377.
- Yin Z, Venkannagari H, Lynch H, Aglyamova G, Bhandari M, Machius M, Nestler EJ, Robison AJ and Rudenko G (2020) Self-assembly of the bZIP transcription factor ΔFosB. Current Research in Structural Biology 2, 1–13.
- Zachariou V, Bolanos CA, Selley DE, Theobald D, Cassidy MP, Kelz MB, Shaw-Lutchman T, Berton O, Sim-Selley LJ, Dileone RJ, Kumar A and Nestler EJ (2006) An essential role for  $\Delta$ FosB in the nucleus accumbens in morphine action. *Nature Neuroscience* **9**, 205–211. DOI: 10.1038/nn1636.
- Zalachoras I, Ramos-Fernández E, Hollis F, Trovo L, Rodrigues J, Strasser A, Zanoletti O, Steiner P, Preitner N and Xin L (2022) Glutathione in the nucleus accumbens regulates motivation to exert reward-incentivized effort. *Elife* 11, e77791.
- Zhang Lei, Huang L, Lu K, Liu Y, Tu G, Zhu M, Ying L, Zhao J, Liu N, Guo F, Zhang Lin and Zhang Lu (2017) Cocaine-induced synaptic structural modification is differentially regulated by dopamine D1 and D3 receptorsmediated signaling pathways. *Addiction Biology* 22, 1842–1855. DOI: 10.1111/adb.12462
- Zhang Y, Crofton EJ, Li D, Lobo MK, Fan X, Nestler EJ and Green TA (2014) Overexpression of deltaFosB in nucleus accumbens mimics the protective addiction phenotype, but not the protective depression phenotype of environmental enrichment. *Frontiers in Behavioral Neuroscience* 8, 297. DOI: 10.3389/fnbeh.2014.00297.
- Zhang Z and Zhao Y (2022) Progress on the roles of MEF2C in neuropsychiatric diseases. *Molecular Brain* 15, 1–11.